Physician profile
David A Vercel
NPI 1225687023
$1,125.46
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $239 · 2022: $476 · 2023: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391 · Entertainment: $19.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.31 |
| Entertainment | $19.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $307.17 | 2021-2023 | Fasenra, Tezspire |
| Abbvie INC. | $113.79 | 2021-2023 | |
| Glaxosmithkline, LLC. | $94.83 | 2021-2023 | Trelegy Ellipta, Arexvy |
| Sunovion Pharmaceuticals INC. | $52.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $51.06 | 2023 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $47.50 | 2022-2023 | |
| Astellas Pharma US INC | $41.12 | 2021-2023 | Myrbetriq |
| Novartis Pharmaceuticals Corporation | $38.16 | 2022 | |
| Sanofi Pasteur INC. | $37.90 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.51 | 2022 | |
| Novo Nordisk INC | $31.72 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $29.79 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $27.01 | 2021-2022 | |
| Pfizer INC. | $26.16 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.34 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.19 | 2023 | Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $22.83 | 2022 | |
| Optos, INC. | $19.31 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Exact Sciences Corporation | $19.28 | 2023 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $19.23 | 2023 | Gemtesa |
| Lilly USA, LLC | $17.39 | 2023 | Mounjaro |
| Nestle Healthcare Nutrition INC. | $16.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.37 | 2022 | |
| Merck Sharp & Dohme LLC | $14.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Vercel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.